In our study, among the gliomas with IDH mutations, the lower‐grade (grade II or III) gliomas accounted for 85.7% (18/21) and the higher‐grade (grade IV) gliomas accounted for 14.3% (3/21). This evidence concerns the gene IDH2 and central nervous system cancer.